Minerva Neurosciences focuses on the clinical development of innovative therapies for central nervous system disorders, particularly schizophrenia and Parkinson's disease. The company emphasizes the importance of designing clinical trials that have endpoints directly related to patient benefits, ensuring that the patients recruited for these trials are those who are likely to benefit from the treatment. This patient-centric approach is a core aspect of their clinical expertise, which aims to advance the understanding and treatment of these complex neurological conditions.

In addition to their clinical focus, Minerva is committed to maintaining a robust pipeline of therapeutic candidates. The company is actively engaged in the development of products that target significant unmet medical needs within the realm of neuroscience. Their efforts are supported by a strong foundation in scientific research and innovation, which is crucial for navigating the complexities of drug development and regulatory approval processes. Minerva's strategic approach aims to enhance the potential for successful commercialization of their therapeutic products, thereby contributing to improved patient outcomes in the field of mental health.

United States

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development of a portfolio of product candidates to treat central nervous system (CNS) diseases. Our goal is to transform the lives of patients with improved therapeutic options.

Central Nervous System (CNS)

Psychological Diseases

Minerva Neurosciences

Central nervous system illness

Mental health

Schizophrenia

<p class="font_7">Roluperidone is meant to block a specific subtype of serotonin receptor &nbsp;called 5-HT2A. When 5-HT2A is blocked, certain symptoms of &nbsp;schizophrenia, such as hallucinations, delusions, agitation and thought &nbsp;and movement disorders, as well as the side effects associated with &nbsp;antipsychotic treatments, can be minimized. Additionally, blocking &nbsp;5-HT2A promotes slow wave sleep, a sleep stage often disrupted in &nbsp;patients with schizophrenia.</p>

Roluperidone (5-HT2A antagonist)

Insomnia

Mood disorders

<p class="font_7">In the brain, the orexin system is involved in the control of several &nbsp;key functions, including metabolism and wakefulness. Seltorexant seeks &nbsp;to inhibit the activity of the neurons that promote wakefulness by &nbsp;selectively blocking the orexin 2 receptor. Rather than making an &nbsp;individual sleepier, blocking the orexin 2 receptor reduces the level of &nbsp;the neurotransmitters that signal the brain to maintain vigilance and &nbsp;wakefulness, which can be helpful for patients with insomnia</p>

Minerva Neurosciences

Company Details